Vikash Khandelia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vikash Khandelia has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Anish Garg
Department of Nephrology, All India Institute of Medical Sciences-Bhubaneswar, Bhubaneswar, India
2 shared publications - Badari Mylliemngap
Department of Nephrology, All India Institute of Medical Sciences-Bhubaneswar, Bhubaneswar, India
2 shared publications Ganesh Srinivasa Prasad
Department of Nephrology, Narayana Health, Bengaluru, India
2 shared publications- Nikunj Kishore Rout
Department of Nephrology, KIMS & PBM Hospital, Bhubaneswar, India
2 shared publications Nitin Kumar
Manipal Hospitals, Patiala, India
2 shared publications- Paromita Das
Department of Nephrology, All India Institute of Medical Sciences-Bhubaneswar, Bhubaneswar, India
2 shared publications
Latest Publications
- Open Access
- 17 February 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
A multicenter prospective real-world cohort study of direct oral anticoagulant use for venous thromboembolism prophylaxis in nephrotic syndrome
Nephrotic syndrome (NS), especially when associated with severe hypoalbuminia, confers a high risk of venous thromboembolism (VTE). While low-molecular-wei
- 17 February 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
Open AccessA multicenter prospective real-world cohort study of direct oral anticoagulant use for venous thromboembolism prophylaxis in nephrotic syndrome
Nephrotic syndrome (NS), especially when associated with severe hypoalbuminia, confers a high risk of venous thromboembolism (VTE). While low-molecular-wei
- Open Access
- 16 December 2025
- Published by Springer Nature in Research Square
A Multicentric prospective Real-World Experience of Direct Oral Anticoagulants use in prophylaxis of Venous Thromboembolism in Nephrotic syndrome
Introduction : Patients with nephrotic syndrome (NS), particularly with severe hypoalbuminia are at significantly increased risk for venous thromboembolism (VTE). Although vitamin K antagonists (VKAs) have traditionally been used for prophylaxis. Evidence supporting direct oral anticoagulants (DOACs) for primary prophylaxis in NS remains scarce, with a lack of prospective real-world data. Methods : We conducted a prospective multicentric cohort study across eight tertiary centers in India, enrolling adults (≥ 18 years) with NS and severe hypoalbuminemia (albumin < 2.4 g/dL for Membranous nephropathy; <2.0 g/dL for other etiologies). All patients received apixaban 5 mg once daily as primary VTE prophylaxis until albumin levels improved beyond 2.4 g/dL. The primary composite outcome included VTE occurrence and major or clinically significant bleeding events. Patients were followed until anticoagulation discontinuation. Results : A total of 212 patients were analyzed (mean age 36.9 ± 14.0 years, 52% male). Median proteinuria was 9.0 g/day and mean serum albumin 1.68 ± 0.49 g/dL; mean serum creatinine was 1.5 ± 0.54 mg/dL. Most patients were categorized as low (80%) or intermediate (20%) bleeding risk by GN tool. Membranous nephropathy was the most common etiology (45%). Immunosuppressive therapy included corticosteroids (81%), rituximab (25.9%), and cyclophosphamide (28.3%). The mean duration of apixaban therapy was 3 months. No venous or arterial thromboembolic events occurred, and minor bleeding was observed in 4 patients (3.5%), all resolving without transfusion or hospitalization. Overall apixaban was well tolerated. Conclusion : This large multicenter prospective study showed that apixaban prophylaxis appears safe, well-tolerated, and potentially effective in preventing VTE among high-risk NS patients. Larger randomized trials are needed to validate findings and optimize dosing, but current data support the rational integration of DOACs into NS thromboprophylaxis protocols.
- 16 December 2025
- Published by Springer Nature in Research Square
Open AccessA Multicentric prospective Real-World Experience of Direct Oral Anticoagulants use in prophylaxis of Venous Thromboembolism in Nephrotic syndrome
Introduction : Patients with nephrotic syndrome (NS), particularly with severe hypoalbuminia are at significantly increased risk for venous thromboembolism (VTE). Although vitamin K antagonists (VKAs) have traditionally been used for prophylaxis. Evidence supporting direct oral anticoagulants (DOACs) for primary prophylaxis in NS remains scarce, with a lack of prospective real-world data. Methods : We conducted a prospective multicentric cohort study across eight tertiary centers in India, enrolling adults (≥ 18 years) with NS and severe hypoalbuminemia (albumin < 2.4 g/dL for Membranous nephropathy; <2.0 g/dL for other etiologies). All patients received apixaban 5 mg once daily as primary VTE prophylaxis until albumin levels improved beyond 2.4 g/dL. The primary composite outcome included VTE occurrence and major or clinically significant bleeding events. Patients were followed until anticoagulation discontinuation. Results : A total of 212 patients were analyzed (mean age 36.9 ± 14.0 years, 52% male). Median proteinuria was 9.0 g/day and mean serum albumin 1.68 ± 0.49 g/dL; mean serum creatinine was 1.5 ± 0.54 mg/dL. Most patients were categorized as low (80%) or intermediate (20%) bleeding risk by GN tool. Membranous nephropathy was the most common etiology (45%). Immunosuppressive therapy included corticosteroids (81%), rituximab (25.9%), and cyclophosphamide (28.3%). The mean duration of apixaban therapy was 3 months. No venous or arterial thromboembolic events occurred, and minor bleeding was observed in 4 patients (3.5%), all resolving without transfusion or hospitalization. Overall apixaban was well tolerated. Conclusion : This large multicenter prospective study showed that apixaban prophylaxis appears safe, well-tolerated, and potentially effective in preventing VTE among high-risk NS patients. Larger randomized trials are needed to validate findings and optimize dosing, but current data support the rational integration of DOACs into NS thromboprophylaxis protocols.
- 1 June 2022
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
- Vol. 16 (6)
A Retrospective Cohort Study on the Risk of Kidney Disease in HIV Positive Individuals Receiving Tenofovir Based Regimens
Introduction: Exposure to Tenofovir often leads to the development of some irreversible high risk for kidney disease events. In Human Immunodeficiency Virus (HIV) patients, the prolonged treatment with tenofovir use frequently causes mildto-moderate nephrotoxicity. Hence, there is a need to further investigate the efficacy and the adverse effects associated with tenofovir use to combat the decreased morbidity and mortality associated with the declined kidney function. Aim: To investigate the risk of kidney disease associated with tenofovir use. Materials and Methods: A retrospective study was conducted at the tertiary care centre in northern India, from August 2009 to January 2017 and analysed during January to May 2021. The patients with HIV infection who were administered Tenofovir, Lamivudine and Efavirenz (TLE) and Zidovudine, Lamivudine and Nevirapine (ZLN) were included.The patients were divided into two group based on the TLE and ZLN regimen they received. These patients were on a regular follow-up for six months. The data was assessed on the basis of serum creatinine and estimated Glomerular Filtration Rate (eGFR) (using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation), body weight and Cluster of Differentiation (CD4) count. Results: Out of 703 patients, 364 patients were administered with TLE, while 339 patients received ZLN. In both the groups, the number of patients were between the age 21-40 years was significantly higher, followed by patients between the age 41- 60 years. The mean weight and CD4 count of the patients in both the groups significantly increased with the progression of time (p0.05. The mean eGFR level was significantly lowered in TLE group (112.2 mL/ min/1.73 m2 ) compared to ZLN group (123.5 mL/min/1.73m2 ) at 24-months follow-up (p<0.001). Conclusion: Overall results demonstrate that increasing exposure to tenofovir was associated with a higher incidence of CKD. The serum creatinine levels were comparable between the TLE and ZLN group.
- 1 June 2022
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
- Vol. 16 (6)
A Retrospective Cohort Study on the Risk of Kidney Disease in HIV Positive Individuals Receiving Tenofovir Based Regimens
Introduction: Exposure to Tenofovir often leads to the development of some irreversible high risk for kidney disease events. In Human Immunodeficiency Virus (HIV) patients, the prolonged treatment with tenofovir use frequently causes mildto-moderate nephrotoxicity. Hence, there is a need to further investigate the efficacy and the adverse effects associated with tenofovir use to combat the decreased morbidity and mortality associated with the declined kidney function. Aim: To investigate the risk of kidney disease associated with tenofovir use. Materials and Methods: A retrospective study was conducted at the tertiary care centre in northern India, from August 2009 to January 2017 and analysed during January to May 2021. The patients with HIV infection who were administered Tenofovir, Lamivudine and Efavirenz (TLE) and Zidovudine, Lamivudine and Nevirapine (ZLN) were included.The patients were divided into two group based on the TLE and ZLN regimen they received. These patients were on a regular follow-up for six months. The data was assessed on the basis of serum creatinine and estimated Glomerular Filtration Rate (eGFR) (using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation), body weight and Cluster of Differentiation (CD4) count. Results: Out of 703 patients, 364 patients were administered with TLE, while 339 patients received ZLN. In both the groups, the number of patients were between the age 21-40 years was significantly higher, followed by patients between the age 41- 60 years. The mean weight and CD4 count of the patients in both the groups significantly increased with the progression of time (p0.05. The mean eGFR level was significantly lowered in TLE group (112.2 mL/ min/1.73 m2 ) compared to ZLN group (123.5 mL/min/1.73m2 ) at 24-months follow-up (p<0.001). Conclusion: Overall results demonstrate that increasing exposure to tenofovir was associated with a higher incidence of CKD. The serum creatinine levels were comparable between the TLE and ZLN group.
- Open Access
- 31 January 2018
- Published by MedCrave Group Kft. in Urology & Nephrology Open Access Journal
- Vol. 6 (1) , 1-6
Comparison of Modified Sutureless Peritoneal Dialysis Catheter Placement with Conventional Technique: A Prospective Study
- 31 January 2018
- Published by MedCrave Group Kft. in Urology & Nephrology Open Access Journal
- Vol. 6 (1) , 1-6
Open AccessComparison of Modified Sutureless Peritoneal Dialysis Catheter Placement with Conventional Technique: A Prospective Study